Cilta-cel, one of the BCMA-targeted CAR-T-cell products with two anti-BCMA single-domain antibodies to present avidity, a CD3-ζ signaling domain, and a 4-1BB costimulatory domain (56), has gotten favorable responses in its phase Ib/II open-label study CARTITUDE-1 from 97 patients with MM who had relapsed after more than three prior LOTs, such as PI, IMiD, or MoABs (56). Here, TNFRSF17 is linked to Miyoshi myopathy.